急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是一类起源于B或T淋巴细胞前体细胞的恶性克隆性肿瘤,其生物学特征和临床预后异质性很大。目前,儿童ALL治疗非常成功,是现代最大的医学成就之一,患者的5年生存率在北美和西欧的大部分国家已接近甚至超过了90%,但是成人ALL的疗效明显不如儿童。近年来,随着新的靶向药物的应用,以及对微小残留病(MRD)检测的深入认识,成人ALL的疗效有望改善。 Acute lymphoblastic leukemia (ALL) is a type of malignant clonal tumor that originates from B or T lymphocyte precursor cells, and its biological characteristics and clinical prognosis are very heterogeneous. Currently, the success of pediatric ALL treatment is one of the greatest medical achievements in modern times. The 5-year survival rate of patients has approached or even exceeded 90% in most countries in North America and Western Europe, but the efficacy of adult ALL is obviously not as good as that of children. In recent years, the efficacy of new adult ALL is expected to improve with new targeted drug applications and in-depth knowledge of minimal residual disease (MRD) testing.